Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.
Shandong Xinhua Pharmaceutical Company Limited has announced the successful completion of Phase I clinical trials for its innovative Alzheimer’s drug, OAB-14 dry suspension, which has shown promising safety and pharmacokinetic results. The company is now preparing to move into Phase II clinical research, signaling progress in the development of its proprietary anti-Alzheimer’s medication. This milestone could be of significant interest to investors and stakeholders monitoring advancements in pharmaceutical treatments for neurodegenerative diseases.
For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.
